Ramp Metals Completes Spring Drill Program and Announces Additional Mineralization at Rush Target
Highlights
20 drill holes totalling 4,942 metres were completed, with every metre being sent for assays
8 holes totalling 2,116 metres were drilled at the Ranger target where 73.55 g/t Au over 7.5m was previously discovered in Ranger-001 drill hole
10 holes were drilled at the Rush target with additional VMS style mineralization intersected in 150m step-out
3 holes for a total of 968 metres were drilled at the Rogue target
Airborne magnetic and TDEM geophysical survey was completed over the remainder of the Rottenstone SW property using the Xcite HTDEM system
"It's exciting to announce that we have completed our spring drill program at the Rottenstone SW property," said Jordan Black, CEO of Ramp Metals. "The program was a huge success completing more holes than originally planned, encountering the quartz diorite package at Ranger and potentially making a new discovery at the Rush target."
Figure 1: Rottenstone SW - 2025 Drill Collar Locations
To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8725/254669_48af8298c4712842_001full.jpg
Ranger
A total of 8 drill holes were completed at the Ranger target (Figure 2). Seven drill holes were completed around the Ranger-001 discovery hole. All 7 holes intersected significant widths of the quartz-diorite package which hosted the previously announced high grade gold intercept of 73.55 g/t Au over 7.5m as reported in the June 17, 2024 News Release.
The remaining hole was designed to test a conductor located approximately 1.5km to the north-east, which was identified in the recently completed airborne geophysics (Figure 3). Altered tonalite and metasediments with Pyrrhotite mineralization were encountered. The hole was ended early at 200m due to time constraints. Management believes that further testing is warranted on the eastern Ranger anomalies.
Figure 2: Ranger - 2025 Drill Hole Collars and Drill Traces
To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8725/254669_48af8298c4712842_002full.jpg
Figure 3: Ranger Drill Collars and Drill Hole Traces with EM
To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8725/254669_48af8298c4712842_003full.jpg
Rush
A total of 10 holes were drilled at the newly identified Rush VMS target (Figure 4). Semi-massive to massive sulphide mineralization was noted in 5 drill holes, with the presence chalcopyrite and sphalerite being confirmed with a Thermo Scientific™ Niton™ XL5 Plus handheld XRF analyzer. Minor amounts of galena were also noted.
Rush-010 intersected net textured to semi-massive sulphide over approximately 4.16m from 21.4m-25.56m (Photo 1). Disseminated to blebby sulphides were also intersected to a depth of approximately 47m (Photo 2). This intersection represents a 150m step-out to the north-east from the initial discovery area where Rush 001, 002, 003, and 009 were drilled. Rush-010 was designed to intercept the outcrop found during the October 2024 field program at depth. Surface rock samples at this outcrop returned values of up to 1.61% copper, 0.79 g/t gold, and 113 g/t silver, as was previously reported in the January 20, 2025 News Release.
Figure 4: Rush - 2025 Drill Collars and Drill Hole Traces
To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8725/254669_48af8298c4712842_004full.jpg
Photo 1: Rush-010 Boxes 5 & 6 - Net textured to semi-massive mineralization from 21.4-25.56m
To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8725/254669_48af8298c4712842_005full.jpg
Photo 2: Rush-010 Boxes 9 & 10 - Disseminated to blebby chalcopyrite mineralization throughout
To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8725/254669_48af8298c4712842_006full.jpg
Rogue
A total of 3 holes were drilled at the Rogue target (Figure 5). These holes were designed to test structural and conductive targets in an area where soil samples of up to 530.7ppb Au were previously reported in the January 20, 2025 News Release. Pyrrhotite and pyrite mineralization was encountered in two of the three holes (Rogue 005 & 006). Rogue 005 & 006 also encountered sections of potassic and hematite altered diorite and fractures (Photos 3 & 4). During the program, drilling at Rogue was limited due to the overall total number of holes covered by the most recent permit package. The Company believes that the Rogue target warrants further exploration to explain the source of the highly anomalous gold in soils.
Figure 5: Rogue - 2025 Drill Collar Locations and Drill Hole Traces
To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8725/254669_48af8298c4712842_007full.jpg
Photo 3: Rogue-005 Boxes 25 & 26 - Potassic alteration of diorite and hematite altered fractures
To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8725/254669_48af8298c4712842_008full.jpg
Photo 4: Rogue-006 Boxes 61 & 62 - Coarse-grained diorite with potassic alteration
To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8725/254669_48af8298c4712842_009full.jpg
Geophysics
The Company has completed a magnetic and TDEM survey over the remainder of the Rottenstone SW property using the Xcite HTDEM system. A total of 3,342 line-km was flown at 100m spacing to provide a high-resolution Mag and EM dataset over the entire property. Data is currently being processed, and the Company will provide a further update once the data processing is completed.
Next Steps
With the present forest fire situation in northern Saskatchewan, the Company felt it prudent to relocate all drill core to a facility in the Prince Albert area to safely complete processing and preparation for assays. The first shipment of samples has been delivered and is being analyzed at Bureau Veritas Commodities Canada Ltd. ("BV") in Vancouver, BC. All remaining core has been fully logged and is currently being cut and sorted for shipping.
The Company plans to return to the Rottenstone SW property for further mapping and sampling once the data from the airborne geophysics and drill programs have been analyzed, and the fire risk has subsided. A ground geophysics program is also planned for the summer to help better define the conductive targets on the property.
An amendment to the current permits requesting up to 30,000m of additional drilling and a 30-person camp is being prepared and is expected to be submitted shortly.
Acknowledgements
Ramp Metals would like to thank the Lac La Ronge Indian Band and all land users for their continued support and working closely with the Company through the permitting process. The Company would also like to thank all the contractors who made the 2025 winter/spring drill program a success.
Drilling: Flamingo Drilling through Athabasca Catering Limited Partnerships
Geology and Geophysics: Axiom Exploration Group Ltd. (Mikaela Miller, Craig Cubbon, Logan Anaka)
Accommodations: Thompson's Resort - Adventure Destinations
Flight Services: Heli-Recon Aerial Support Services Inc. and Osprey Wings Ltd.
Fuel Services: Millsap Fuel Distributors Ltd.
Local Contractors: Cecil Mcleod, Alex Mcleod, Bradley McKenzie, Ethan Ballantyne, Joey McKenzie, Chris Roberts, Joe Stanley, Jimmy McKenzie, Riley Provencher
Quality Assurance/Quality Control
Uncut whole NQ drill core was analyzed by a Thermo Scientific™ Niton™ XL5 Plus handheld XRF, operated by Ramp Metals staff on site. The Portable X-Ray Fluorescence ("pXRF") data is exploratory in nature and is used predominantly as an internal workflow to assist in target prioritization and mineral identification through an early phase of exploration investigation. pXRF data is not provided as it is not an indicator of representative geochemistry of the entire rock mass and therefore should only be viewed as an initial screening prior to laboratory assays.
Drill core is currently being sampled and cut by diamond saw. Samples will be shipped as they are processed for laboratory analysis at BV, an internationally recognized and ISO 17025:2017 accredited analytical services provider, at its Vancouver, BC laboratory.
Drill core samples are marked in maximum intervals of up to 1.5m and cut in half using a diamond saw with half sent for assay and the other half saved for reference. Samples are then bagged and zip-tied, with 15 bagged samples placed into sealed rice bags and then 20 rice bags placed in mega bags for transport to BV. Sample QA/QC procedures were applied by inserting a regular and systematic schedule of standards, blanks and duplicates into the sample stream. Control samples consisting of certified reference samples and blank samples were systematically inserted into the sample stream and analyzed as part of the Company's QA/QC protocol at a rate of 1:15 or better in addition to BV's internal quality assurance programs.
Rock samples are prepared using the PRP70-250 package, where samples are weighed, dried, and crushed to greater than 70% passing a 2mm sieve, then pulverized to greater than 85% passing 75 microns. Samples are analyzed in accordance with BV's MA300 and FA330 packages, for both multi-element ICP analysis (0.25 g, multi-acid and ICP-ES analysis) and gold analysis by fire assay (30g fire assay with AAS finish). Gold returning >10ppm is automatically analyzed by gravimetric method in accordance with BV's standard of practice.
Qualified Person
Brett Williams, P.Geo., VP Operations and Senior Geologist for Ramp Metals, and a "qualified person" under National Instrument 43-101 Standards of Disclosure for Mineral Projects, has reviewed and approved the technical content in this news release.
About Ramp Metals Inc.
Ramp Metals is a grassroots exploration company with a focus on a potential new Saskatchewan gold district. The Company currently has a new high-grade gold discovery of 73.55 g/t Au over 7.5m at its flagship Rottenstone SW property. The Rottenstone SW property comprises 32,715 hectares and is situated in the Rottenstone Domain.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
FORWARD-LOOKING STATEMENTS
This news release contains "forward-looking statements" within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking statements. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or may contain statements that certain actions, events or results "may", "could", "would", "might" or "will be taken", "will continue", "will occur" or "will be achieved". The forward-looking information and forward-looking statements contained herein include, but are not limited to, statements regarding the Company's exploration activities.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: requirements for additional capital; future prices of minerals; changes in general economic conditions; changes in the financial markets and in the demand and market price for commodities; other risks of the mining industry; the inability to obtain any necessary governmental and regulatory approvals; changes in laws, regulations and policies affecting mining operations; hedging practices; and currency fluctuations.
Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
For further information, please contact:
Ramp Metals Inc.
Jordan BlackChief Executive Officerjordaneblack@rampmetals.com
Prit SinghDirector905 510 7636
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/254669
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
2 hours ago
- Miami Herald
Vision Marine Technologies Reports $8.2M in 7-Week Boat Sales, Highlighting Post-Acquisition Growth Impact
MONTREAL, QC / ACCESS Newswire / August 12, 2025 / Vision Marine Technologies Inc. (NASDAQ:VMAR) ("Vision Marine" or the "Company"), a leader in electric marine propulsion and multi-brand boat retail, today announced a significant increase in sales performance-highlighted by accelerated boat sales revenue, a significant reduction in floor plan liabilities, and stronger inventory turnover-following the recent acquisition of Nautical Ventures Group Inc. ("Nautical Ventures"). From June 20, 2025 to August 8, 2025, the newly acquired Nautical Ventures division generated approximately US$8.2 million in gross revenue through boat sales-compared to Vision Marine's total boat sales of $1.4 million for its entire fiscal year ended August 31, 2024. This short-term performance reflects a 504% increase relative to the Company's prior full-year sales and highlights the transformational impact of the acquisition, expanded retail footprint and integrated sales infrastructure. This top-line expansion was accompanied by a 44% reduction in floor plan financing, declining from approximately US$56.1 million as of December 31, 2024, to US$31.3 million as of August 8, 2025. This reduction underscores Vision Marine's focus on financial discipline, operational streamlining, and enhanced sales execution. Inventory turnover has also accelerated. Between June 20, 2025 and August 8, 2025, the Company reduced its product inventory by approximately US$4.9 million, driven by increased demand across both internal combustion engine ("ICE") and electric boat categories. Vision Marine is also expanding into the tender boat segment. As announced in July, the Company is leveraging Nautical Ventures' role as a leading U.S. distributor of Highfield Boats, which sold more than 600 tenders from 2022 to 2024 and generated over $14 million in related revenue. A new dedicated Fort Lauderdale facility now serves as a high-volume hub for tender sales and service. In parallel, the Company saw a 900% year-over-year increase in inbound boat leads through the addition of Nautical Ventures' sales channels, attributed to the availability of new product lines and a performance-driven marketing strategy. This demand directly supports Vision Marine's growth across both electric and ICE segments. "We want to be clear with investors: this is a materially different Vision Marine than it was last year," said Alexandre Mongeon, CEO of Vision Marine. "Through the acquisition of Nautical Ventures, we've added real sales volume, operational scale, and a platform capable of accelerating both electric and traditional boat sales." Vision Marine will provide additional updates on its financial results and strategic milestones in its Q4 2025 release in November. Preliminary and Unaudited Financial Information The financial information presented in this release is preliminary, unaudited, and subject to change. These results have not been reviewed by the Company's independent registered public accounting firm and may differ materially from results to be included in the Company's upcoming filings with the U.S. Securities and Exchange Commission ("SEC"). Use of Non-GAAP Financial Measures This press release includes references to "gross revenue," which may be considered a non-GAAP financial measure. Management uses this metric internally to evaluate performance; however, it should not be viewed as a substitute for, or superior to, measures calculated in accordance with IFRS. A reconciliation to GAAP financial measures will be provided, as necessary, in future filings with the SEC. Cautionary Note Regarding Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These statements reflect current expectations and projections about future events and are not guarantees of future performance. Actual results may differ materially from those expressed or implied due to various risks and uncertainties, including, but not limited to, integration risks related to the acquisition of Nautical Ventures, market demand, and operational execution. Vision Marine undertakes no obligation to update or revise any forward-looking statements except as required by law. Investor and Company Contact:Bruce NurseInvestor Relations(303) 919‑2913bn@v‑ SOURCE: Vision Marine Technologies Inc
Miami Herald
2 hours ago
- Miami Herald
MIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabalin
Manuscript accepted for publication in Frontiers in Pharmacology, "Oral Administration of Ketamir-2, a Novel Ketamine Analog, Attenuates Neuropathic Pain in Rodent Models via Selective NMDA Antagonism" details Ketamir-2's superior performance in two validated neuropathic pain models and supports advancement to Phase 2a clinical trials by year-end 2025. MIAMI, FL / ACCESS Newswire / August 12, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced the acceptance of a second peer-reviewed manuscript describing its lead oral drug candidate, Ketamir-2, in Frontiers in Pharmacology. The newly accepted publication reports that Ketamir-2 outperformed ketamine, pregabalin, or gabapentin-depending on the comparator used-in restoring sensory function and reversing pain behaviors across two gold-standard rodent models of neuropathic pain. The findings build on MIRA's first publication characterizing Ketamir-2's clean pharmacology and favorable safety profile and align with the Company's plan to initiate a Phase 2a trial in neuropathic pain by year-end 2025. Market Opportunity Neuropathic pain represents a significant and underserved market across North America. Epidemiology suggests approximately 7-10% of the population experiences neuropathic pain; in North America, this equates to approximately 36-51 million people across the U.S., Canada, and Mexico. According to Precedence Research, the global neuropathic pain market is valued at approximately $7.97 billion in 2024 and is projected to reach $16.79 billion by 2034, growing at a compound annual growth rate (CAGR) of 7.73%. North America accounts for a significant share of this market, representing an estimated $3.7-3.9 billion annually today. The U.S. neuropathic pain market is estimated at $2.79 billion in 2024 and is projected to reach $5.92 billion by 2034, growing at a CAGR of 7.80% over the same period. Growth is expected to be driven by rising prevalence of diabetes, cancer survivorship, and aging-related nerve damage, underscoring the large and expanding commercial potential for novel treatments such as Ketamir-2. Ketamir-2's differentiated mechanism, oral bioavailability, and superior performance in gold-standard preclinical models position it as a potential next-generation, non-opioid treatment option in this multi-billion-dollar and rapidly growing market. Key Findings from the Publication Chung Model (sciatic nerve ligation in rats)Male rats: Ketamir-2 restored sensory thresholds toward baseline, while ketamine-tested as the comparator-showed no measurable rats: Ketamir-2 outperformed both pregabalin and gabapentin, delivering greater and more consistent restoration of normal sensory (PTX)-Induced Neuropathy in MiceGabapentin was the sole comparator in this chemotherapy-induced neuropathy model. Ketamir-2 produced more complete normalization of pain sensitivity in both male and female cohorts, while gabapentin provided only partial or inconsistent Across Genders and SpeciesDespite differences in baseline pain sensitivity between male and female animals, Ketamir-2 demonstrated clear and significant therapeutic benefit in every cohort tested. Mechanistic Differentiation Ketamir-2 is a new molecular entity that selectively binds to the PCP site of the NMDA receptor with low affinity and shows no significant interaction with over 40 other receptor systems, including serotonin, dopamine, and opioid receptors. This combination of selectivity, oral bioavailability, and demonstrated efficacy in gold-standard models suggests the potential for a differentiated, next-generation therapeutic option in neuropathic pain. "The acceptance of this second peer-reviewed publication is another important milestone for our Ketamir-2 program," said Erez Aminov, CEO of MIRA. "The data clearly demonstrate superior and more consistent pain relief compared to leading neuropathic pain drugs, within the specific models tested. This provides additional confidence as we advance Ketamir-2 toward Phase 2a clinical evaluation and continue to explore its potential in broader CNS applications." "The robust reversal of pain sensitivity observed in these well-validated preclinical models-whether compared to ketamine, pregabalin, or gabapentin-further supports Ketamir-2's potential as a differentiated, orally administered treatment for neuropathic pain," added Dr. Itzchak Angel, Chief Scientific Advisor. "Given the limited number of effective oral treatments for this indication, Ketamir-2's profile is especially compelling." Clinical Development Update Phase 1 Trial Progressing: The ongoing Phase 1 trial of Ketamir-2 in Israel is on schedule, with no safety concerns reported to date and the single ascending dose portion nearing 2a by Year-End: MIRA plans to submit a Phase 2a clinical trial protocol to the U.S. Food and Drug Administration (FDA) in Q4 2025 as an advanced development version to its active IND, with the goal of initiating the study in neuropathic pain by Beyond Neuropathic Pain: With its clean pharmacology and oral bioavailability, Ketamir-2 is also being explored for potential applications in depression, anxiety, post-traumatic stress disorder (PTSD), and as a topical formulation for localized pain conditions. The full publication will be available upon release at: About MIRA Pharmaceuticals, Inc. MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in areas such as neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. Cautionary Note Regarding Forward-Looking Statements This press release and the statements of MIRA's management related thereto contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA's current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA's potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA's programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 14A filed by MIRA on June 18, 2025, and other SEC filings, which are on file with the SEC at and on MIRA's website at MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact:Helga Moyainfo@ 432-9792 SOURCE: MIRA Pharmaceuticals
Business Wire
2 hours ago
- Business Wire
Law Offices of Howard G. Smith Encourages SelectQuote, Inc. (SLQT) Investors To Inquire About Securities Fraud Class Action
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased SelectQuote, Inc. ('SelectQuote' or the 'Company') (NYSE: SLQT) securities between , inclusive (the 'Class Period'). SelectQuote investors have until October 10, 2025 to file a lead plaintiff motion. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN SELECTQUOTE, INC. (SLQT), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? On May 1, 2025, the U.S. Department of Justice ('DOJ') filed a False Claims Act complaint against SelectQuote, alleging, '[f]rom 2016 through at least 2021' SelectQuote received 'tens of millions of dollars' in 'illegal kickbacks' from health insurance companies in exchange for steering Medicare beneficiaries to enroll in the insurers' plans. Further, SelectQuote, in exchange for kickbacks, engaged in a conspiracy with major insurers to illegally discriminate against beneficiaries deemed to be less profitable, including those with disabilities. The DOJ concluded that SelectQuote made materially false claims by stating it offers 'unbiased coverage comparisons' when in fact it 'repeatedly directed Medicare beneficiaries to the plans offered by insurers that paid them the most money, regardless of the quality or suitability of the insurers' plans.' On this news, SelectQuote's stock price fell $0.61, or 19.2%, to close at $2.56 per share on May 1, 2025, on unusually heavy trading volume. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the Company was directing Medicare beneficiaries to the plans offered by insurers that best compensated SelectQuote, regardless of the quality or suitability of the insurers' plans; (2) that SelectQuote did not provided unbiased comparison shopping for Medicare Advantage insurance plans; (3) that SelectQuote received illegal kickbacks to steer Medicare beneficiaries to certain insurers and limit enrollment in competitors' plans; (4) that as a result, SelectQuote had not complied with applicable laws, regulations, and contractual provisions; (5) that SelectQuote was vulnerable to regulatory and legal sanctions as a result of its conduct, including claims that it had violated the False Claims Act; and (6) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. Contact Us To Participate or Learn More: If you purchased SelectQuote securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at: This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
